Differences between responsive and intractable chronic lymphocytic leukemia.
About 19-26% of patients with chronic lymphocytic leukemia (CLL) have intractable disease resistant to chemotherapy, have a relatively short median survival time and are responsive to splenectomy. Lymphocytes from patients with intractable CLL are resistant in vitro to X-irradiation and to colchicine. Responsive CLL is an accumulative disease while intractable CLL is a proliferative disease.